| 张一琼 顾丽琴.吉西他滨联合奈达铂治疗复发性卵巢癌临床疗效观察[J].实用中西医结合临床,2015,15(9):5-7 |
| 吉西他滨联合奈达铂治疗复发性卵巢癌临床疗效观察 |
| The Therapeutic Effect of Gemcitabine Combined with Nedaplatin in the Treatment of the Recurrent Ovarian Cancer |
| |
| DOI： |
| 中文关键词: 复发性卵巢癌 吉西他滨联合奈达铂 化学治疗 |
| 英文关键词: Recurrent ovarian cancer Gemcitabine combined with nedaplatin Chemotherapy |
| 基金项目: |
|
| 摘要点击次数: 714 |
| 全文下载次数: 408 |
| 中文摘要: |
| 目的：观察吉西他滨联合奈达铂治疗复发性卵巢癌的临床疗效。方法：将43例卵巢癌术后复发患者分为治疗组23例及对照组20例，治疗组采用吉西他滨+奈达铂治疗，对照组采用紫杉醇类药物+奈达铂治疗，均化疗4~6个疗程，观察两组总有效率、化疗不良反应、CA-125化疗前后的变化及CA-125值与肿物的大小关系。结果：所有患者均完成4~6个疗程的化疗，治疗组CR 12例，PR 6例，总有效率达78.3%；对照组CR 4例，PR 3例，总有效率35.0%，治疗组总有效率明显高于对照组（P＜0.05）；化疗不良反应血液系统及消化系统反应无明显差异（P＞0.05），脱发及过敏反应优于对照组（P＜0.05）；治疗组治疗后CA-125值明显低于复发化疗前，差异有统计学意义（P＜0.01），治疗组化疗后与对照组化疗后CA-125值比较，差异无统计学差异（P＞0.05）；8例对紫杉醇耐药患者均有较好的疗效。结论：选择适量的吉西他滨+奈达铂是治疗复发性卵巢癌的较佳方案，值得进一步推广。 |
| 英文摘要: |
| Objective: To observe the effect of gemcitabine combined with nedaplatin in the treatment of the recurrent ovarian cancer. Methods: 43 Postoperative recurrent ovarian cancer patients were divided into two groups, 20 patients in the therapy group and 23 patients in the control group. Gemcitabine combined with nedaplatin was used in the therapy group, paclitaxel and nedaplatin was used in the control group. Chemotherapy time lasted for 4 to 6 courses in both groups. The effective rates, adverse reactions, the relationship between tumor size and the change of CA-125 value before and after chemotherapy were observed and were statistically analyzed. Results: All patients were completed 4 to 6 courses of chemotherapy. CR of 12 cases and PR of 6 cases in the therapy group were occurred; meanwhile CR of 4 cases and PR of 3 cases in the control group, the effective rates were 78.3% and 35.0% respectively. It showed that effectiveness in therapy group was higher than the control group (P＜0.05); there were no significant differences in the adverse reactions of the blood system and the digestive system between two groups (P＞0.05); the incidence of baldness and anaphylactic reaction in the therapy group was significant lower than that in the control group (P＜0.05). After therapy, the CA-125 values was significantly lower than that before treatment (P＜0.01), there were no significant differences in the CA-125 values after treatment between two groups (P＞0.05); 8 patients which were resistant to paclitaxel had good efficacy. Conclusion: The chemotherapy of taking appropriate dosage of gemcitabine combined with nedaplatin is a good way to treat the recurrent ovarian cancer, it worth generalizing in clinic treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
